|
業務類別
|
-- |
|
業務概覽
|
Lundbeck is a Denmark-based pharmaceutical firm that focuses on the development and commercialization of central nervous system drugs including antidepressants, antipsychotics, and antiepileptic products. The company's portfolio includes Abilify Maintena and Rexulti for psychosis, Brintellix/Trintellix for depression, Northera for Parkinson's disease symptoms, Sabril and Onfi for seizures, and Vyepti for migraine prevention. Most of the company's sales are derived in North America, followed by Asia and Europe. |
| 公司地址
| Ottiliavej 9, Valby, DNK, 2500 |
| 電話號碼
| +45 36301311 |
| 傳真號碼
| +45 36301940 |
| 公司網頁
| https://www.lundbeck.com |
| 員工數量
| 5268 |
| Mr. Charl van Zyl |
President and Chief Executive Officer |
-- |
04/02/2026 |
| Mr. Joerg Hornstein |
Chief Financial Officer and Executive Vice President, Corporate Functions. |
-- |
04/02/2026 |
|
|
| Mr. Lars Green |
Independent Director |
04/02/2026 |
| Mr. Hossein Armandi |
Director |
04/02/2026 |
| Ms. Dorte Clausen |
Director |
04/02/2026 |
| Mr. Lasse Skibsbye |
Director |
04/02/2026 |
| Ms. Lene Skole Sorensen |
Deputy Chairman of the Board |
04/02/2026 |
| Ms. Camilla Gram Andersson |
Director |
04/02/2026 |
| Mr. Jakob Riis |
Director |
04/02/2026 |
| Mr. Jeffrey Berkowitz |
Independent Director |
04/02/2026 |
| Dr. Santiago Arroyo |
Independent Director |
04/02/2026 |
| Mr. Lars Erik Holmqvist |
Director |
04/02/2026 |
| Dr. Ilse Dorothea Wenzel |
Chairman of the Board |
04/02/2026 |
|
|
|
|
